Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) is a publicly traded Healthcare sector company. As of May 21, 2026, RXRX trades at $2.95 with a market cap of $1.53B and a P/E ratio of -2.04. RXRX moved +4.04% today. Year to date, RXRX is -32.27%; over the trailing twelve months it is -34.95%. Its 52-week range spans $2.77 to $12.36. Analyst consensus is buy with an average price target of $7.38. Rallies surfaces RXRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
RXRX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. RXRX recently traded at $2.95. Market cap is $1.53B. P/E ratio is -2.04. Revenue is $74.68M.
| Metric | Value |
|---|---|
| Price | $2.95 |
| Market Cap | $1.53B |
| P/E Ratio | -2.04 |
| EPS | $-1.44 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.36 |
| 52-Week Low | $2.77 |
| Volume | 63.79K |
| Avg Volume | 0 |
| Revenue (TTM) | $74.68M |
| Net Income | $-644.76M |
| Gross Margin | 4.99% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $74.68M | $-644.76M | $-1.44 |
| 2024 | $58.84M | $-463.66M | $-1.69 |
| 2023 | $44.58M | $-328.07M | $-1.58 |
| 2022 | $39.84M | $-239.48M | $-1.36 |
5 analysts cover RXRX: 0 strong buy, 2 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.38.